Reaction
Dysplasia reporting signals
As of the last recalculation, Dysplasia appears in 1,176 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is VINCRISTINE SULFATE (PRR 26.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Vincristine Sulfate | 42 | 26.3 | 26.3 |
| Doxepin Hydrochloride | 18 | 25.6 | 25.6 |
| Ifosfamide | 30 | 25.3 | 25.4 |
| Doxepin | 14 | 24.7 | 24.8 |
| Fludarabine Phosphate | 44 | 20.5 | 20.6 |
| Polatuzumab Vedotin | 11 | 20.1 | 20.2 |
| Sirolimus | 15 | 19.9 | 20.0 |
| Meperidine Hydrochloride | 9 | 17.4 | 17.4 |
| Doxorubicin Hydrochloride | 28 | 15.5 | 15.5 |
| Mesna Injection | 7 | 15.1 | 15.1 |
| Bendamustine Hcl | 13 | 15.0 | 15.0 |
| Mesna | 7 | 14.8 | 14.8 |
| Azacitidine For | 15 | 14.8 | 14.8 |
| Everolimus Tablets | 13 | 13.9 | 13.9 |
| Bendamustine Hydrochloride | 9 | 13.4 | 13.4 |
| Loperamide Hydrochloride Oral | 7 | 12.2 | 12.2 |
| Doxorubicin | 53 | 11.0 | 11.0 |
| Azacitidine | 18 | 10.9 | 10.9 |
| Cytarabine | 35 | 10.6 | 10.6 |
| Venetoclax | 35 | 10.3 | 10.3 |
| Axicabtagene Ciloleucel | 5 | 9.0 | 9.0 |
| Cyclophosphamide Injection, Solution | 84 | 9.0 | 9.0 |
| Cyclophosphamide | 84 | 9.0 | 9.0 |
| Cyclophosphamide For Injection | 84 | 9.0 | 9.0 |
| Vedolizumab | 41 | 8.7 | 8.7 |
| Etoposide | 35 | 8.7 | 8.7 |
| Ranitidine Hydrochloride | 26 | 8.6 | 8.6 |
| Teduglutide | 6 | 7.9 | 7.9 |
| Palivizumab | 3 | 3.5 | 3.5 |